Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04833582 · ClinicalTrials.gov registry record · Phase 1
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
A Phase 1 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04833582 is a Phase 1 study that has completed, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT04833582, a Phase 1 study, has completed, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a phase 1/2 study of azenosertib (ZN-c3) in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
Interventions
- DRUG Gemcitabine
- DRUG Azenosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04833582
The ClinicalTrials.gov registry entry for NCT04833582 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT04833582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04833582 about?
NCT04833582 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma". This is a phase 1/2 study of azenosertib (ZN-c3) in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
What is the current status of trial NCT04833582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-08-01. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT04833582?
The interventions under investigation include: Gemcitabine (DRUG), Azenosertib (DRUG).
Who is sponsoring clinical trial NCT04833582?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.